Published in Eur Heart J on December 23, 2013
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol (2015) 0.92
Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet (2015) 0.86
The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. Atherosclerosis (2015) 0.84
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans. Sci Transl Med (2016) 0.79
Injection site reactions after subcutaneous oligonucleotide therapy. Br J Clin Pharmacol (2016) 0.79
Liver histology during Mipomersen therapy for severe hypercholesterolemia. J Clin Lipidol (2014) 0.78
Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel. Curr Vasc Pharmacol (2015) 0.77
Current therapies for lowering lipoprotein (a). J Lipid Res (2015) 0.77
Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers. Mol Ther (2016) 0.77
Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia. Drugs (2015) 0.76
Development of Antisense Drugs for Dyslipidemia. J Atheroscler Thromb (2016) 0.76
No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects. Eur J Clin Pharmacol (2015) 0.76
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis (1999) 3.33
Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31
Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med (1990) 3.17
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2013) 1.96
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J (2012) 1.79
Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.74
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation (2008) 1.55
Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation (2011) 1.51
Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol (2012) 1.43
Optimal management of familial hypercholesterolemia: treatment and management strategies. Vasc Health Risk Manag (2010) 1.16
Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract (2008) 1.14
Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res (2009) 1.13
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One (2012) 1.10
Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. Adv Clin Chem (2011) 1.07
Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol Rev (2012) 0.92
Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs (2011) 0.91
Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia. Drugs Today (Barc) (2011) 0.83
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol (2015) 1.88
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther (2016) 1.46
Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. Atherosclerosis (2017) 0.75